The Trump administration will not give Utah or other states federal funding to partially expand their Medicaid programs under the Affordable Care Act; if a Medicare for all system operates the same way as traditional Medicare, the program would be “wastefully expensive,” authors warn; the creator of the widely used screening test to screen for early signs of cognitive decline is insisting on training for those who administer it.
The Trump administration will not give Utah or other states federal funding to partially expand their Medicaid programs under the Affordable Care Act, The Washington Post reported. CMS authorized the state to move forward on a so-called “partial expansion” earlier this year to a limited number of people. Utah had hoped to receive additional US funding even though it was not fully expanding Medicaid. According to the report, the White House claimed that it did not make sense to approve the more generous funding while arguing in court at the same time that the entire ACA should be overturned.
What would a Medicare for all system cover? Most people are focused on taxes and access, but in a New York Times column, Austin Frakt, PhD, and Elsa Pearson, MPH, noted that unlike in other countries, which often refuse to pay for therapies where the cost exceeds the benefits, traditional Medicare rarely denies claims. In a 2018 report to Congress, the Medicare Payment Advisory Commission noted that up to one-third of beneficiaries received some kind of low-value treatment in 2014, costing the program billions of dollars. If Medicare for all operated the same way, the program would be “wastefully expensive,” they wrote.
The creator of the widely used screening test to screen for early signs of cognitive decline is insisting on training for those who administer it, Kaiser Health News reported. Starting September 1, most clinicians who administer the Montreal Cognitive Assessment (MoCA) will be required to complete a 1-hour, $125 online course. Ziad Nasreddine, MD, said increasing concerns about the validity of test results, as well as possible liability for errors, spurred the changes. The test was used last year by President Donald Trump’s then-physician, who said the president scored a 30 out of 30.
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen